Regulation of metastasis-related gene expression by p53: A potential clinical implication

Molecular Carcinogenesis

Volumn 24, Issue 1, 1999, Pages 25-28

  Sun, Yi ^a   Wicha, Max ^b   Leopold, Wilbur R ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Inhibitor of matrix metalloproteinases; Metastasis related gene; P53; Radiation; Radiotherapy; Tumor metastasis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53; THROMBOSPONDIN 1; UVOMORULIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DNA DAMAGE; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; METASTASIS; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CATHEPSIN D; DNA DAMAGE; DNA, NEOPLASM; GELATINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; THROMBOSPONDIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032962581     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199901)24:1<25::AID-MC4>3.0.CO;2-S     Document Type: Article

References (32)

1. Lewin DI. Evolutions: Metastasis. Journal of NIH Research 1996;8:82-87.
2. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Semin Cancer Biol 1996;7:147-154.
3. Greene GF, Kitadai Y, Pettaway CA, von Eschenbach AC, Bucana CD, Fidler IJ. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 1997;150:1571-1582.
4. Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-1051.
5. Singh RK, Gutman M, Reich R, Bar-Eli M. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res 1995;55:3669-3674.
6. Leto G, Gebbia N, Rausa L, Tumminello FM. Cathepsin D in the malignant progression of neoplastic diseases. Anticancer Res 1992;12:235-240.
7. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
8. Ko LJ, Prives C. p53: Puzzle and paradigm. Genes Dev 1996;10:1054-1072.
9. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
10. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF-1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
11. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-299.
12. Wu GS, Burns TF, McDonald III ER, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;7:141-143.
13. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389:300-305.
14. Ludes-Meyers JH, Subler MA, Shivakumar CV, et al. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 1996;17:6009-6019.
15. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A, matrix metalloproteinase-2) promoter. Mol Cell Biol 1997;17:6330-6338.
16. Wu GS, Saftig P, Peters C, El-Deiry WS. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 1998;16:2177-2183.
17. Mashimo T, Watabe M, Hirota S, et al. The expression of the KAl1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 1998;1130-1131.
18. Ueba T, Nosaka T, Takahashi JA, et al. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1994;91:9009-9013.
19. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459-462.
20. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL. Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch 1997, 431:317-321.
21. Nathanson SD, Westrick P, Anaya P, et al. Relationship of spontaneous regional lymph node metastases to dose of local irradiation of primary B16 melanomas. Cancer Res 1989;49: 4412-4416.
22. Kastan MB, Canman CE, Leonard CJ. p53, cell cycle control and apoptosis: Implications for cancer. Cancer Metastasis Rev 1995;14:3-15.
23. Lowe SW, Ruley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-967.
24. Brown P. Matrix metalloproteinase inhibition: A novel anti-cancer strategy. Pharmaceutical News 1995;2:29-32.
25. Sun Y, Hegamyer G, Cheng YJ, et al. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci USA 1992;89:6516-6520
26. Sun Y. Molecular oncology of human nasopharyngeal carcinoma. Cancer Journal 1995;8:325-330.
27. Al-Sarraf M, McLaughlin PW. Nasopharynx carcinoma: Choice of treatment. Int J Radiat Oncol Biol Phys 1995;33:761-763.
28. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 1996; 93:1093-1096.
29. Yandell DW, Thor AD. p53 analysis in diagnostic pathology. Biologic implications and possible clinical applications. Diagn Mol Pathol 1993;2:1-3.
30. Wu CS, Pollack A, Czerniak B, et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 1996;47:305-310.
31. Lane DP. p53, guardian of the genome. Nature 1992;358: 15-16.
32. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-1586.